-
Scientific rationale
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages.
Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more. New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants. -
Programme
10.00 Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly 10.30 Gene expression tools inbearly-stage HR+/HER2- breast cancer: when and which one? Gaia Griguolo 11.00 Biological insights of the immune system in breast cancer Moderatore: Maria Vittoria Dieci 11.30 DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones? Mafalda Oliveira 12.00 Tackling diversity in HER2-positive breast cancer: biological and clinical implications Tomas Pascual 12.30 Discussion
13.00 Lunch
SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
The changing relationship between locoregional recurrences and long-term outcomesChairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas 14.00 Mapping local and regional recurrences Orit Kaidar-person 14.30 The surgical perspective Moderatore: Eleftherios Mamounas 15.00 Deciphering the EBCTCG meta-analyses Philip Poortmans 15.30 Discussion
Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly 16.00 Clinical case 1. Skin flap thickness for IBR 16.15 Clinical case 2. When to resect/irradiate after systemic therapy for a recurrence Luca Visani 16.30 Clinical case 3: Local recurrence after DCIS
Eleonora Ferrara 16.45 General discussion and concluding comments
Jacek Jassem, Hesham Ahmed Gaballah Elghazaly 17.00 Adjourn
17.15 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023 17.30 Lecture of the Awardee
18.00 Adjourn
SESSION III – EARLY BREAST CANCER Chairpersons: Alessandra Gennari, Valentina Guarneri 9.00 New therapeutic strategies in very young women: lights and shadows Angela Toss 9.20 Elderly patients: how old is too old in the contemporary scenario Laura Biganzoli 9.40 Neoadjuvant approach: rethinking the paradigm? Federica Miglietta 10.00 New ESMO Guidelines Valentina Guarneri 10.20 Discussion 10.50 Coffee break
Multidisciplinary Tumor Board 2 - Early breast cancer Panelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Philip Poortmans 11.15 Clinical case 1. Genomic test in premenopausal patients Davide Massa 11.30 Clinical case 2. Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic risk Michele Bottosso 11.45 Clinical case 3. HER2+ cT1c N0: adjuvant or neoadjuvant? Ottavia Amato 12.00 General discussion and concluding comments Moderatore: Alessandra Gennari 12.30 Lunch
SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS Chairpersons: Giuseppe Curigliano, Pierfranco Conte 13.30 HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance? Stephen Johnston 14.00 HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristics Sandra Swain M 14.30 Triple negative disease: something more than label indications to dictate treatment sequence? Hope Rugo 15.00 Discussion
Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo 15.30 Clinical case 1. Visceral crisis
Grazia Maria Vernaci 15.45 Clinical case 2. Oligometastatic disease
Cristina Falci 16.00 Clinical case 3. Leptomeningeal metastases Carlo Alberto Giorgi 16.15 General discussion and concluding comments Hope Rugo 16.30 Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat -
Faculty
Pierfranco Conte Venezia Valentina Guarneri Padova Philip Poortmans Wolrijk-antwerp (Belgio) Aleix Prat Barcellona (Spagna) Ottavia Amato Milano Laura Biganzoli Prato Bettina Borisch Geneva (Svizzera) Michele Bottosso Padova Giuseppe Curigliano Milano Maria Vittoria Dieci Padova Hesham Ahmed Gaballah Elghazaly Cairo (Egitto) Cristina Falci Padova Eleonora Ferrara Novara Alessandra Gennari Novara Oreste Davide Gentilini Milano Carlo Alberto Giorgi Padova Gaia Griguolo Padova Jacek Jassem Stephen Johnston Londra (Regno Unito) Orit Kaidar-person Ramat Gan (Israele) Sibylle Loibl Francoforte (Germania) Eleftherios Mamounas -1 Orlando - Florida (Stati Uniti D'America) Davide Massa Padova Federica Miglietta Padova Mafalda Oliveira -1 Barcellona (Spagna) Tomas Pascual Barcellona (Spagna) Hope Rugo San Francisco (Stati Uniti D'America) Sandra Swain M Washington (Stati Uniti D'America) Angela Toss Modena Grazia Maria Vernaci Padova Luca Visani Firenze -
How to participate the meeting
Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.
-
Registration
Participation registration fees
- Quota di partecipazione intera € 120.00
- Per specializzandi € 80.00
For eligibility criteria and other information on reduced fees (if applicable), contact info.bologna@accmed.org.
To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee) by 16/09/2023. Payment can be made online exclusively with Credit Cards or Paypal.
If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.
In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.
-
CME Instructions
To obtain CME credits, users must meet the following requirements:
- Their declared profession/specialization must correspond to those accredited for CME.
- They must attend at least 90% of the course.
- They must complete the online meeting evaluation form.
- They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.
The learning assessment test and meeting evaluation form must be submitted within three days of the event.
Please note that in order to access the learning assessment test, users must (A) register at the course venue and (B) submit the online meeting evaluation form.
Certificate of attendance
To download the certificate of attendance, users must have registered at the course venue.
If their attendance is less than 75% of the stated duration, the certificate will reflect the percentage of attendance.
We strongly encourage users to keep track of their personal badge and the badge recordings by the AccMed personnel, it is users' responsibility to have their attendance recorded accurately.
-
Training objective
Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere